Allergy, Immunology and Pulmonology clinicians (MDs, DOs and APPs)
Asthma, Severe asthma, Biomarkers, Symptom scales, Exacerbations, Asthma control
Clinical Associate Professor, Medicine
University of Arizona College of Medicine
Associate Clinical Director, Allergy Clinic
Banner University Medical Group
Tucson, AZ
Dr. Puneet Shroff is a board-certified Allergist & Immunologist who joined the University of Arizona in the Division of Pulmonary, Allergy, Critical Care & Sleep Medicine in 2018. He is also a Clinical Associate Professor of Medicine. Dr. Shroff came to Tucson after having built a thriving Allergy & Immunology practice in Houston from 2012 to 2018. He has a keen clinical acumen and a deep understanding of allergy clinic workflow, including allergy testing and immunotherapy. During his time in Houston, Dr. Shroff also served on the Board of the Greater Houston Allergy, Asthma & Immunology Society.
Dr. Shroff received his Doctor of Medicine in Chicago, IL and then completed residency in Internal Medicine at Washington University in St. Louis. He then trained at Baylor College of Medicine in Houston, TX where he completed a dual fellowship in Allergy & Immunology and Rheumatology and served as Chief Fellow. Dr. Shroff has studied internationally, including the University of Oxford, and he is a Certified Instructor in Yoga, including asana and pranayama (breathing) practices. He also has additional training in Integrative Medicine through the Arizona Center for Integrative Medicine founded by Dr. Andrew Weill.
Associate Professor of Internal Medicine and Pediatrics
Division of Allergy and Immunology, University of South Florida
Associate Director, Clinical Research Unit
Director, Post-Graduate Education, Division of Allergy and Immunology
Juan Carlos Cardet, MD, MPH received his BS degree from Harvard University, Cambridge, Massachusetts in 2004; medical degree from the University of Puerto Rico, San Juan, Puerto Rico in 2008; and master’s in public health degree from Harvard University, Boston, Massachusetts in 2017. He completed his internal medicine training at the University of Connecticut in 2011, where he was given the Maxwell O. Phelps, M.D. award for scholarship, and the Hartford Hospital Outpatient Clinic Resident of the Year Award. He completed his Allergy and Immunology training at Brigham and Women’s Hospital/Harvard University in 2014. He served as an instructor in medicine at Harvard Medical School, and as the assistant director of the Asthma Research Center at Brigham and Women’s Hospital from 7/2014—6/2017.
Dr. Cardet specializes in the treatment of patients with asthma and other allergic and immunologic diseases. He is board certified in Allergy and Immunology, and he is a fellow of the American Academy and College of Allergy Asthma and Immunology (AAAAI and ACAAI). He is the chair of the Allergy and Asthma in Older Adults committee and secretary of the Asthma Diagnosis and Treatment interest section of the AAAAI.
His work focuses on mechanisms-based therapeutics for allergic and immunologic diseases. He conducts clinical and translational research and has been awarded NIH K23, R21 and U awards as well as several industry-sponsored and foundation grants for his projects.
| 1. | DIFFERENTIATE among currently approved asthma biologics based on patient phenotype, biomarker profiles, and clinical indications to select the most appropriate therapy for individualized care. |
| 1. | DIFFERENTIATE among currently approved asthma biologics based on patient phenotype, biomarker profiles, and clinical indications to select the most appropriate therapy for individualized care. |

In collaboration with
Acknowledgement of Commercial Support
This activity is supported by an educational grant from Regeneron
Title: Biologic therapies in severe/uncontrolled asthma
Release | Expiration: December 19, 2025 – December 19, 2026
Statement of Need:
Biologic therapies targeting IgE, IL-5, IL-4Rα, and TSLP have reshaped the landscape for severe asthma, allowing for personalized, phenotype-driven care. These agents offer options for patients who remain symptomatic despite maximal inhaled therapy. Several biologics are currently approved, with dupilumab and tezepelumab among the most recent additions. This expanded toolkit offers flexibility in treatment selections, yet it can also make decisions more complicated for asthma specialists and primary care providers alike.
Specialists, including allergists and pulmonologists, lead in diagnosing complex cases, conducting phenotyping, and initiating biologic therapy. However, they are often unsure how to choose among the available biologics, particularly when indications overlap, or patient profiles vary. Questions also remain around when to switch agents, taper therapy, or apply biomarker data to personalize long-term care.
This curriculum has been developed for asthma specialists and will focus on optimizing the use of biomarkers and treatment algorithms to personalize biologic selection, sequencing, and de-escalation strategies in complex or refractory asthma cases.
Educational Objective:
DIFFERENTIATE among currently approved asthma biologics based on patient phenotype, biomarker profiles, and clinical indications to select the most appropriate therapy for individualized care
Target Audience:
Allergy, Immunology and Pulmonology clinicians (MDs, DOs and APPs)
Faculty:
![]() | Karla E. Adams, MD, FAAAAI, FACAAI, FAAP |
| Disclosures | Dr. Adams has no relevant disclosures |
|
| Juan Carlos Cardet, MD, MPH |
| Disclosures | Dr. Cardet has the following relevant relationships: Aiolosbio, Amgen, Apogee, AstraZeneca, Chiesi, Genentech, Sanofi (advisory board) |
|
| Puneet Shroff, MD, FAAAAI, FACAAI |
| Disclosures | Dr. Shroff has no relevant disclosures |
Technical Writer:
Lynne Kolton Schneider, PhD
Disclosures
No relevant financial disclosures
Jordana Goldman, MD
Disclosures
No relevant financial disclosures
Accredited Provider Disclosure:
None of the planners, reviewers, and AAAAI and RealCME staff for this educational activity have relevant financial relationship(s) with ineligible companies to disclose.
Disclosure of Financial Relationships Policy:
AAAAI adheres to the ACCME’s Standards for Integrity and Independence in Accredited Continuing Education. Any individuals in a position to control the content of a CME/CE activity, including faculty, planners, reviewers, or others are required to disclose all financial relationships with ineligible entities (commercial interests). All relevant conflicts of interest have been mitigated prior to the commencement of the activity.
Accredited Provider & Accreditation Statements:
This activity is accredited through AAAAI.
CME: The American Academy of Allergy Asthma and Immunology (AAAAI) is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.
CE: The American Academy of Allergy Asthma and Immunology (AAAAI) is a Provider approved by the California Board of Registered Nursing, Provider #10704.
Credit Designation Statement:
The AAAAI designates this activity for up to 0.25 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Disclosure of Unlabeled Use:
This activity may or may not discuss investigational, unapproved, or off-label use of drugs. Participants are advised to consult prescribing information for any products discussed. The information provided in this activity is for continuing education purposes only and is not meant to substitute for the independent medical judgment of a clinician relative to diagnostic and treatment options for a specific patient's medical condition.
Disclaimer:
The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of AAAAI and RealCME. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.
If you have any questions relating to the accreditation of this activity, please contact cme@aaaai.org
Method of Participation/Instructions:
Please proceed with the activity until you have successfully completed this program, answered all test questions, and evaluation, and have received a digital copy of your credit certificate.
Privacy Statement:
The American Academy of Allergy, Asthma & Immunology (AAAAI) takes your privacy seriously. AAAAI will only use your personal information to administer your registration, attendance, and credit claiming/attendance record for this activity, to provide services that you have requested from AAAAI and otherwise as you may expressly consent. A complete copy of AAAAI’s Legal and Privacy Notices, the terms of which are incorporated herein, can be found here.
By providing consent, you are allowing AAAAI to process your personal data. AAAAI will collect and store information you provide in the Registration Forms for the purposes of enabling us to register your attendance at the activity; to assist with administrative, planning and marketing purposes; and to allow the compilation and analysis of statistics relevant to AAAAI.
The information you provide in the Registration Forms, and information provided at any other time during this activity, including without limitation any feedback obtained during the activity, will be used by AAAAI to offer, provide and continue to improve its educational activities and other services. The AAAAI may also use your email address to communicate important information regarding this activity and for marketing purposes for future activities. AAAAI will not otherwise, without your consent, use or disclose your personal information for any purpose unless it would reasonably be expected that such a purpose is related to the offer, provision and improvement of the activity or where such purpose is permitted or required by law.
I understand that it is my right to withhold consent to the above Privacy and Data Protection Notice, or to withdraw my previous consent at any time. I further understand that without my consent, it is not possible to process my registration/housing request for this activity. Please contact the AAAAI Education Team at (414) 272-6071 if you have any further questions about how this will affect your registration request for this activity.
COURSE VIEWING REQUIREMENTS
| Supported Browsers: Microsoft Edge Google Chrome 60 or higher Mozilla Firefox 60 or higher Apple Safari 11.0 or higher For video, install the latest version of Quicktime. | Supported Phones & Tablets: iOS 9.3 and higher Android 7.0 (Nougat or higher) Microsoft Windows 8 Chrome OS |
| Additional Recommendations and Requirements | |
| Display Resolution & Color Depth | Resolution - 960 X 768 minimum - 1024 X 768 recommended min. Color Depth - 8 bits (256 colors) minimum - 16 bits (High colors) minimum |
| Audio | - Microphone - Speakers or headphones - Audio recording support |
| Word Processing | Software that can open, modify, and save documents in Rich Text Format (RTF). Microsoft Word and PowerPoint are recommended. |